US FDA proposals on risk-based clinical trial monitoring and their implications for medical device manufacturers
This article was originally published in SRA
Executive Summary
Nancy J Stark discusses the Food and Drug Administration's draft guidance on overseeing clinical investigations and considers the pros and cons of the proposals for device manufacturers.